RESUMEN
Brain metastases ( BM ) are a frequent complication of non-small cell lung cancer (NSCLC), with various treatment strategies. The widespread use of tyrosine kinase inhibitor (TKI) has significantly prolonged the survival of NSCLC patients with epidermal growth factor receptor mutations. This article reviews recent progress in TKI therapy for BM in NSCLC patients and discusses a combination of TKI and radiotherapy.
RESUMEN
Brain metastases ( BM ) are a frequent complication of non-small cell lung cancer (NSCLC), with various treatment strategies. The widespread use of tyrosine kinase inhibitor (TKI) has significantly prolonged the survival of NSCLC patients with epidermal growth factor receptor mutations. This article reviews recent progress in TKI therapy for BM in NSCLC patients and discusses a combination of TKI and radiotherapy.